LAG525 Solid and Hematologic Malignancies trial completed, page-11

Meanwhile other I/O players gaining momentum:
'Libtayo first line treatment in advanced NSCLCC prolongs survival - early phase 3 data".
In addition to improving survival, Libtayo increased the proportion of people who responded to treatment, and lowered their risk of death or disease progression, compared with chemo.
The study’s findings were recently presented as a late-breaking abstract at ESMO, titled “EMPOWER-Lung 1"
Developer - Regeneron in collaboration with Sanofi. 710 participants. Libtayo increased patients survival from 14.3 months (standard of care- chemo) to 22.1 months (Libtayo - mono).
Noting:-
“In new analyses presented at ESMO, Libtayo reduced the risk of death by 43% in patients whose cancer had confirmed PD-L1 expression of 50% or greater.
Perhaps Efti could further improve 'allcomer' PD-L1 expression as it currently is doing with Pembro?